Thomas J. Schuetz bought $21k of CMPX
CHIEF EXECUTIVE OFFICER at Compass Therapeutics, Inc.. 10,000 shares at an average of $2.11, traded May 27, 2025, filed May 27, 2025.
Score components
- +25RoleCEO
- 0Trade size$21k at market
- -5Relative to holdingsUnder 1% of holdings (0.2%)
- +8Price context46% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001171843-25-003462, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 27, 2025 | POpen-market purchase Common Stock | +10,000 | $2.11 | $21k | 6,480,825 | May 27, 2025 |
Related signals
Other insiders at Compass Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 41Moderate | CMPXbuy Compass Therapeutics, Inc. | Neil Lerner Chief Accounting Officer | $18k 20,000 shares | +5% | |
| 28Weak | CMPXbuy Compass Therapeutics, Inc. | Neil Lerner Chief Accounting Officer | $2,850 2,500 shares | +1% | |
| 68Notable | Compass Therapeutics, Inc. | Orbimed Advisors LLC director, owner | $5.7M 3,571,428 shares | -100% | |
| 68Notable | Compass Therapeutics, Inc. | Carl L Gordon director, owner | $5.7M 3,571,428 shares | -100% | |
| 46Moderate | Compass Therapeutics, Inc. | Jonathan Anderman Gen Counsel & Corporate Sec | $31k 20,000 shares | +2000% | |
| 39Weak | Compass Therapeutics, Inc. | Neil Lerner CHIEF ACCOUNTING OFFICER | $28k 20,000 shares | +7% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.